MYC and cancer: Importantly, the expression of GS in cancer seems to be regulated by oncogenic players such as Myc [164], KRAS, and PI3K [165], indicating that the cancer cells’ genetic profile can limit the expression of GS and consequently their capacity of de novo producing glutamine.